Affordable Access

deepdyve-link
Publisher Website

[Clinical effect and safety of 144-week treatment with entecavir capsules in treatment-naïve HBeAg-positive patients with chronic hepatitis B].

Authors
  • Cai, D C1
  • Pan, C2
  • Yu, W H3
  • Dang, S S4
  • Li, J5
  • Wu, S M6
  • Jiang, N7
  • Wang, M R8
  • Zhang, Z H9
  • Lin, F10
  • Xin, S J11
  • Yang, Y F12
  • Shen, B S13
  • Ren, H1
  • 1 The Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China. , (China)
  • 2 Mengchao Hepatobiliary Hospital of Fujian Medical University, Fuzhou 350000, China. , (China)
  • 3 The Eighth People's Hospital of Guangzhou, Guangzhou 510060, China. , (China)
  • 4 The Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China. , (China)
  • 5 The Second People's Hospital of Tianjin, Tianjin 300192, China. , (China)
  • 6 Shanghai Public Health Clinical Center, Shanghai 201508, China. , (China)
  • 7 Sichuan Provincial People's Hospital, Chengdu 610772, China. , (China)
  • 8 No.81 Hospital of PLA, Nanjing 210002, China. , (China)
  • 9 Jinan Infectious Disease Hospital, Jinan 250021, China. , (China)
  • 10 Hainan General Hospital, Haikou 570311, China. , (China)
  • 11 No.302 Hospital of PLA, Beijing 100039, China. , (China)
  • 12 The Second Hospital of Nanjing, Nanjing 210003, China. , (China)
  • 13 The First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China. , (China)
Type
Published Article
Journal
Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology
Publication Date
Aug 20, 2017
Volume
25
Issue
8
Pages
597–600
Identifiers
DOI: 10.3760/cma.j.issn.1007-3418.2017.08.008
PMID: 29056009
Source
Medline
Keywords
License
Unknown

Abstract

目的: 评价恩替卡韦胶囊治疗HBeAg阳性慢性乙型肝炎初治患者的有效性、安全性。 方法: 158例HBeAg阳性的慢性乙型肝炎患者接受口服恩替卡韦胶囊抗病毒治疗,1次/d,每次0.5 mg,共144周。于基线、24周、48周、72周、96周、120周和144周均监测患者疗效及安全性。计数资料采用Fisher精确概率检验。 结果: 经过144周治疗,病毒学应答率(HBV DNA<69 IU/ml)为90.91%,丙氨酸氨基转移酶复常率为88.18%,HBeAg转阴率为33.33%,HBeAg血清转换率为24.07%;因不良事件退出2例,发生严重不良反应5例。 结论: 恩替卡韦胶囊治疗HBeAg阳性慢性乙型肝炎初治患者具有强效抑制病毒复制的作用及良好的安全性。.

Report this publication

Statistics

Seen <100 times